<DOC>
	<DOC>NCT01835353</DOC>
	<brief_summary>This is a prospective, multi-center, non-randomized, controlled study in 2 sequential groups of P2Y12 inhibitor-naive consecutive STEMI patients undergoing primary PCI. Following aspirin 325 mg LD, patients will receive 60 mg or 100 mg of prasugrel, respectively. Platelet reactivity (PR)will be assessed at Hour 0 (before prasugrel's administration immediately prior to PCI) and at Hours 0.5, 1, 2, 4 thereafter. Platelet function testing (in PRU) will be performed with the VerifyNow (Accumetrics Inc., San Diego, CA, USA) P2Y12 function assay.</brief_summary>
	<brief_title>High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>ST elevation myocardial infarction Pain onset &lt;12 hours Age &gt;18 and &lt;75 years Written informed consent history of stroke/transient ischemic attack oral anticoagulation hemodynamic instability platelet count &lt;100000/Î¼L hematocrit &lt;30% creatinine clearance &lt;30 ml/min severe hepatic dysfunction active bleeding weight &lt;60 Kg periprocedural IIb/IIIa inhibitor administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>prasugrel</keyword>
	<keyword>ST elevation myocardial infarction</keyword>
</DOC>